Breaking the relapse barrier: innovative approaches to improve CAR T-cell efficacy by targeting leukemic stem cells (LSCs) and measurable residual disease (MRD) in acute myeloid leukemia.
Novel CAR-T approaches targeting leukemia stem cells offer a path to reduce relapse—the biggest hurdle today.
Review of innovative CAR-T strategies specifically targeting leukemic stem cells (LSCs) and measurable residual disease (MRD) to overcome the major cause of relapse after CAR-T therapy in AML. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- review
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Int Immunopharmacol
Why it surfaced
Comprehensive review of an emerging and clinically urgent area; AML CAR-T has lagged significantly behind B-cell malignancy CAR-T; LSC targeting is recognized as essential for durable remissions; published in a relevant journal with an abstract confirming full treatment of the subject.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.